Early initiation of long-acting injectable antipsychotic treatment is associated with lower hospitalization rates and healthcare costs in patients with schizophrenia: real-world evidence from US claims data

References

• Weinberger DR, Harrison PJ, editors. Schizophrenia: Weinberger/Schizophrenia [Internet]. Oxford: Wiley-Blackwell; 2010 [cited 2018 Feb 9]. Available from: http://doi.wiley.com/10.1002/9781444327298.
   Google Scholar
• NIMH. Schizophrenia [Internet]. [cited 2018 Jan 12]. 2016 Bethesda, MD. Available from: https://www.nimh.nih.gov/health/topics/schizophrenia/index.shtml.
   Google Scholar
• Cloutier M, Aigbogun MS, Guerin A, et al. The economic burden of schizophrenia in the United States in 2013. J Clin Psychiatry. 2016;77:764–771.
   PubMed Web of Science ®Google Scholar
• Stovall J. Bipolar disorder in adults: Epidemiology and pathogenesis [Internet]. UpToDate. 2016. Website access date 2018 Jan 12; location Waltham, MA; publisher date 2018 Feb 6. Available from: https://www.uptodate.com/contents/bipolar%C2%ADdisorder%C2%ADin%C2%ADadults%C2%ADepidemiology%C2%ADand%C2%ADpathogenesis/print?source=search_result&search=bipolar%20stovall&select%E2%80%A6.
   Google Scholar
• Naudet F, Maria AS, Falissard B. Antidepressant response in major depressive disorder: a meta-regression comparison of randomized controlled trials and observational studies. PLoS One. 2011;6:e20811.
   PubMed Web of Science ®Google Scholar
• Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161:1–56.
   PubMed Web of Science ®Google Scholar
• Haas GL, Garratt LS, Sweeney JA. Delay to first antipsychotic medication in schizophrenia: impact on symptomatology and clinical course of illness. J Psychiatr Res. 1998;32:151–159.
   PubMed Web of Science ®Google Scholar
• Marshall M, Rathbone J. Early intervention for psychosis. Cochrane Database Syst Rev. 2011;CD004718.
   PubMedGoogle Scholar
• de Haan L, Linszen DH, Lenior ME, et al. Duration of untreated psychosis and outcome of schizophrenia: delay in intensive psychosocial treatment versus delay in treatment with antipsychotic medication. Schizophr Bull. 2003;29:341–348.
   PubMed Web of Science ®Google Scholar
• Stevens GL, Dawson G, Zummo J. Clinical benefits and impact of early use of long‐acting injectable antipsychotics for schizophrenia. Early Interv Psychiatry. 2016;10:365–377.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Adherence to long-term therapies: evidence for action [Internet]. World Health Organization; 2003 [cited 2018 Jan 25]. Geneva 27, Switzerland. Available from: http://books.google.com/books?hl=en&lr=&id=kcYUTH8rPiwC&oi=fnd&pg=PR5&dq=%22VI+%E2%80%93+How+can+improved+adherence+be+translated+into%22+%22XIII+%E2%80%93%22+%22III+%E2%80%93+Disease-specific%22+%22VIII+%E2%80%93+Cancer+(palliative%22+%22XI+%E2%80%93%22+%22X+%E2%80%93%22+%22VII+%E2%80%93%22+%22XII+%E2%80%93%22+&ots=tz5Kir5cv_&sig=c5FxwOS1GP1PLX8P5yKo_CJzhyA.
   Google Scholar
• Haddad P, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas. 2014;5:43.
   PubMedGoogle Scholar
• Lafeuille M-H, Frois C, Cloutier M, et al. Factors associated with adherence to the HEDIS quality measure in medicaid patients with schizophrenia. Am Health Drug Benefits. 2016;9:399–410.
   PubMed Web of Science ®Google Scholar
• Velligan DI, Sajatovic M, Hatch A, et al. Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Prefer Adherence. 2017;11:449–468.
   PubMed Web of Science ®Google Scholar
• Bright CE. Measuring medication adherence in patients with schizophrenia: an integrative review. Arch Psychiatr Nurs. 2017;31:99–110.
   PubMed Web of Science ®Google Scholar
• Yang J, Ko Y-H, Paik J-W, et al. Symptom severity and attitudes toward medication: impacts on adherence in outpatients with schizophrenia. Schizophr Res. 2012;134:226–231.
   PubMed Web of Science ®Google Scholar
• García S, Martínez-Cengotitabengoa M, López-Zurbano S, et al. Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: a systematic review. J Clin Psychopharmacol. 2016;36:355–371.
   PubMed Web of Science ®Google Scholar
• El-Mallakh P, Findlay J. Strategies to improve medication adherence in patients with schizophrenia: the role of support services. Neuropsychiatr Dis Treat. 2015;11:1077.
   PubMed Web of Science ®Google Scholar
• De las Cuevas C, de Leon J, Peñate W, et al. Factors influencing adherence to psychopharmacological medications in psychiatric patients: a structural equation modeling approach. Patient Prefer Adherence. 2017;11:681–690.
   PubMed Web of Science ®Google Scholar
• Pesa JA, Muser E, Montejano LB, et al. Costs and resource utilization among medicaid patients with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics. Am Health Drug Benefits . 2015;2:377–385.
   Google Scholar
• Bergeson JG, Kalsekar I, Jing Y, et al. Medical care costs and hospitalization in patients with bipolar disorder treated with atypical antipsychotics. Am Health Drug Benefits. 2012;5:379–386.
   PubMedGoogle Scholar
• Greenberg PE, Fournier A-A, Sisitsky T, et al. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015;76:155–162.
   PubMed Web of Science ®Google Scholar
• Lafeuille M-H, Gravel J, Lefebvre P, et al. Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics. J Med Econ. 2013;16:1290–1299.
   PubMedGoogle Scholar
• Greene M, Yan T, Chang E, et al. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. J Med Econ. 2018;21:127–134.
   PubMed Web of Science ®Google Scholar
• Yan T, Greene M, Chang E, et al. All-cause hospitalization and associated costs in patients with schizophrenia or bipolar disorder initiating long-acting injectable antipsychotics. Curr Med Res Opin. 2018;34:41–47.
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2014;40:192–213.
   PubMed Web of Science ®Google Scholar
• Francey SM, Nelson B, Thompson A, et al. Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention. Schizophr Res. 2010;119:1–10.
   PubMed Web of Science ®Google Scholar
• Girardi P, Del Casale A, Rapinesi C, et al. Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone palmitate and aripiprazole monohydrate. Hum Psychopharmacol Clin Exp. 2018;33:e2658.
   PubMed Web of Science ®Google Scholar
• Parellada E, Andrezina R, Milanova V, et al. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. J Psychopharmacol. 2005;19:5–14.
   PubMed Web of Science ®Google Scholar
• Emsley R, Chiliza B, Asmal L, et al. Long-acting injectable antipsychotics in early psychosis: a literature review. Early Interv Psychiatry. 2013;7:247–254.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Long-acting injectable antipsychotics: shall the last be first? CNS Spectr. 2014;19:3–5.
   PubMed Web of Science ®Google Scholar
• Kim B, Lee S-H, Yang YK, et al. Long-acting injectable antipsychotics for first-episode schizophrenia: the pros and cons. Schizophr Res Treat. 2012;2012:1–8.
   Google Scholar
• Taylor M, Ng KYB. Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review. Aust N Z J Psychiatry. 2013;47:624–630.
   PubMed Web of Science ®Google Scholar
• Brugnoli R, Rapinesi C, Kotzalidis GD, et al. Model of Management (Mo.Ma) for the patient with schizophrenia: crisis control, maintenance, relapse prevention, and recovery with long-acting injectable antipsychotics (LAIs). Riv Psichiatr. 2016;51:47–59.
   PubMed Web of Science ®Google Scholar
• Bartzokis G, Lu PH, Amar CP, et al. Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory. J Chronic Dis. 2011;132:35–41.
   Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.
   PubMedGoogle Scholar
• Chi M, Lee C, Wu S. The prevalence of chronic conditions and medical expenditures of the elderly by chronic condition indicator (CCI). Arch Gerontol Geriatr. 2011;52:284–289.
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Schooler NR, Weedon JC, et al. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. J Clin Psychiatry. 2009;70:1397–1406.
   PubMed Web of Science ®Google Scholar
• Barrio P, Batalla A, Castellví P, et al. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case–control study. Int Clin Psychopharmacol. 2013;28:164–170.
   PubMed Web of Science ®Google Scholar
• Kane JM, Kishimoto T, Correll CU. The comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse: a case study in CER in psychiatry. J Clin Epidemiol. 2013;66:S37–S41.
   PubMed Web of Science ®Google Scholar
• Lin J, Wong B, Offord S, et al. Healthcare cost reductions associated with the use of LAI formulations of antipsychotic medications versus oral among patients with schizophrenia. J Behav Health Serv Res. 2013;40:355–366.
   PubMed Web of Science ®Google Scholar
• Kim B, Lee S-H, Choi TK, et al. Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1231–1235.
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168:603–609.
   PubMed Web of Science ®Google Scholar
• Willis M, Svensson M, Löthgren M, et al. The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden. Eur J Health Econ. 2010;11:585–594.
   PubMed Web of Science ®Google Scholar
• Offord S, Wong B, Mirski D, et al. Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral. J Med Econ. 2013;16:231–239.
   PubMedGoogle Scholar
• Kane JM, Sanchez R, Zhao J, et al. Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia. J Med Econ. 2013;16:917–925.
   PubMedGoogle Scholar
• Crivera C, DeSouza C, Kozma CM, et al. Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE). BMC Psychiatry. 2011;11:168.
   PubMed Web of Science ®Google Scholar
• Bera R, Offord S, Zubek D, et al. Impact on healthcare resource usage and costs among Medicaid-insured schizophrenia patients after initiation of treatment with long-acting injectable antipsychotics. J Med Econ. 2013;16:522–528.
   PubMedGoogle Scholar
• Achilla E, McCrone P. The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia. Appl Health Econ Health Policy. 2013;11:95–106.
   PubMedGoogle Scholar
• Correll CU, Citrome L, Haddad PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77:1–24.
   PubMed Web of Science ®Google Scholar
• Kirschner M, Theodoridou A, Fusar-Poli P, et al. Patients’ and clinicians’ attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis. Ther Adv Psychopharmacol. 2013;3:89–99.
   PubMedGoogle Scholar
• Potkin S, Bera R, Zubek D, et al. Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia. BMC Psychiatry. 2013;13:261.
   PubMed Web of Science ®Google Scholar
• Sacchetti E, Grunze H, Leucht S, et al. Long-acting injection antipsychotic medications in the management of schizophrenia. Evid-Based Psychiatr Care. 2015;1:27–36.
   Google Scholar